AI assistant
DEXCOM INC — Director's Dealing 2022
Sep 12, 2022
30198_dirs_2022-09-12_dfa51cc3-f24e-47f7-ac47-afa4119ea6de.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2022-09-08
Reporting Person: Selvaraj Shelly Ramasamy (SVP Chief Information Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-09-08 | Common Stock | A | 4051 | $0.001 | Acquired | 49942 | Direct |
Footnotes
F1: This RSU Award was granted pursuant to the Amended and Restated 2015 Equity Incentive Plan, in a transaction exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement.
F2: Adjusted to reflect Dexcom's 4-for-1 stock split, effective on June 10, 2022. Included in this number are 31,107 unvested restricted stock units, 4,051 of which were granted on September 8, 2022 and shall all vest on September 8, 2023, 11,556 of which were granted on March 8, 2022 and shall vest through March 8, 2025, 8,192 of which were granted on March 8, 2021 and shall vest through March 8, 2024, 7,308 of which were granted on March 8, 2020 and shall vest through March 8, 2023.